Hepatitis C treatment experts are recommending a revised pricing strategy implemented at the state level that could help a greater number of affected patients access the treatment, according to a report published in Annals of Internal Medicine.
“These innovative therapies can cure hepatitis C, but the high costs put them out of reach for the most vulnerable populations,” said lead report author Neeraj Sood, PhD. “We wanted to come up with a better solution where we dramatically improve access to cures, control drug spending but still maintain incentives for the development of new cures.”
The researchers targeted the novel pricing strategy at state policymakers, outlining ways to leverage competition among drug manufacturers. The strategy aims to save states money and ensure a greater number of patients can be treated.